Related Experiment Video
Updated: Aug 4, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Targeting Rab26 to Conquer Cisplatin-Resistant Lung Cancer with Self-Assembled DNA Nanomaterials
Beinuo Wang1,2, Ruijie Zhang3, Yao Wang4
1Department of Thoracic Surgery, West China Hospital of Medicine, Sichuan University, Chengdu 610044, China.
Abstract:
Overcoming cisplatin-based drug resistance in lung cancer remains an enormous challenge in clinical tumor therapy worldwide. Recent studies have reported that some Rab GTPases are involved in multiple aspects of tumor progression, including invasion, migration, metabolism, autophagy, exosome secretion, and drug resistance. In particular, Rab26 is essential to vital processes such as vesicle-mediated secretion, cell growth, apoptosis, and autophagy. In this study, we developed a nanosystem based on programmed DNA self-assembly of Rab26 siRNA-loaded nanoparticles (siRNP). We demonstrated that siRNP could be effectively transfected into cisplatin-resistant A549 (A549/DDP) cells. These siRab26-carrying nanoparticles induced apoptosis and inhibited the disruption of autophagy. The combination therapy of siRab26 knockdown with cisplatin could improve the antitumor therapy compared with a single one in vitro. In nude mice, siRNP enhanced the chemosensitivity of cisplatin-resistant cells and inhibited tumor xenograft development. These outcomes suggest that siRNP is an effective platform for lung cancer therapy in cases exhibiting drug resistance.
Insights
This study introduces Rab26 siRNA nanoparticles (siRNP) to combat cisplatin resistance in lung cancer. siRNP effectively targets resistant cells, enhancing chemotherapy and inhibiting tumor growth.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Cisplatin resistance is a major obstacle in lung cancer treatment.
- Rab GTPases, including Rab26, play roles in tumor progression and drug resistance.
Purpose of the Study:
- To develop a novel nanosystem for overcoming cisplatin resistance in lung cancer.
- To investigate the therapeutic potential of Rab26 siRNA-loaded nanoparticles (siRNP).
Main Methods:
- Programmed DNA self-assembly was used to create siRNP.
- siRNP was transfected into cisplatin-resistant A549/DDP cells.
- In vitro and in vivo studies were conducted using cell lines and nude mice models.
Main Results:
- siRNP effectively delivered Rab26 siRNA into resistant lung cancer cells.
- siRab26 induced apoptosis and prevented autophagy disruption.
- Combination therapy with siRNP and cisplatin showed improved antitumor effects.
- siRNP enhanced chemosensitivity and suppressed tumor xenograft growth in vivo.
Conclusions:
- siRNP is a promising platform for enhancing lung cancer therapy, particularly in drug-resistant cases.
- Targeting Rab26 with siRNA delivered via nanoparticles offers a potential strategy to overcome cisplatin resistance.
